A Mab A Case Study In Bioprocess Development ^hot^ Jun 2026
Upstream development focused on maximizing specific productivity while maintaining critical quality attributes (CQAs) such as glycosylation profiles. Cell Line Development (CLD)
The primary goal of upstream development is to maximize volumetric productivity while ensuring the critical quality attributes (CQAs) of the mAb remain within predefined limits. Cell Line Development
"A-Mab: A Case Study in Bioprocess Development" is a 2009 document from the CMC Biotech Working Group illustrating the application of Quality by Design (QbD) principles to monoclonal antibody manufacturing. The 278-page study details the development, design space, and control strategies for a hypothetical product. Download the complete case study from International Society for Pharmaceutical Engineering (ISPE) A–Mab: A Case Study in Bioprocess Development - ISPE
: The study defines "design spaces"—the multidimensional combination of input variables (e.g., pH, temperature) that ensure quality—allowing for more flexible regulatory filings. 2. Key Stages of Bioprocess Development A Mab A Case Study In Bioprocess Development
A step gradient using 50 mM sodium acetate at pH 3.5 cleanly eluted the bound mAb.
The selected cell line, CHO-A Mab, was then adapted to grow in a serum-free medium, which is essential for large-scale production.
Develop a robust process capable of seamless technology transfer to a 2,000L pilot facility. The 278-page study details the development, design space,
The first chapter of the mAb manufacturing story is upstream processing (USP), which focuses on creating a master cell line and an optimal environment for it to produce therapeutic antibodies. The primary goal is to achieve high productivity without sacrificing complex product quality.
The A-Mab case study, developed by the CMC Biotech Working Group, serves as a foundational guide for applying Quality by Design (QbD) principles to monoclonal antibody production. It outlines crucial strategies for defining Target Product Profiles and establishing design spaces in upstream and downstream processing to ensure product quality. Read the full case study at International Society for Pharmaceutical Engineering (ISPE) A–Mab: A Case Study in Bioprocess Development - ISPE
No significant impact on titer or product quality up to 2,000 L. Key Stages of Bioprocess Development A step gradient
The A Mab case study refers to the development of a bioprocess for the production of a monoclonal antibody used in the treatment of a specific disease. The project involved a collaboration between a biotechnology company and a contract manufacturing organization (CMO) to develop a commercial-scale bioprocess for A Mab.
The dihydrofolate reductase (DHFR) selection system was utilized, employing methotrexate (MTX) to drive gene amplification.
